Download
1 / 30
390 likes | 566 Views
Histamine. Histamine is a chemical messenger that mediates a wide range of cellular response, including allergic and inflammatory reactions, gastric acid secretion, and neurotransmission in brain.
E N D
Histamine is a chemical messenger that mediates a wide range of cellular response, including allergic and inflammatory reactions, gastricacid secretion, and neurotransmission in brain. Histamine has no clinical applications, but agents interfere with the action of histamine ( antihistamines ) have important therapeutic applications.
Synthesis: histamine is an amine formed by the decarboxylation of the amino acid histidine by histidine decarboxylase, an enzyme that is expressed in cells throughout the body, including central nervous system neurons, gastric-mucosa parietal cells, mast cells, and basophils. In mast cells, histamine is stored in granules as an inactivecomplex composed of histamine, heparin and anionic protein.
Release of histamine: The release of histamine may be the primary response to some stimuli including allergies, anaphylaxis, celldestruction as result of cold, bacterial toxins, bee stings or trauma. In most of cases, histamine is just one of several chemical mediators released.
Mechanism of histamine action: Histamine released in response to various stimuli exerts its effects by binding to one or more of four types of histamine receptors; H1, H2, H3 and H4 receptors. H1 and H2 receptors are widelyexpressed and are the targets of clinicallyuseful drugs. H3 and H4 receptors are expressed in only fewcell types, and their roles in drug action are unclear. Histamine has notherapeutic use but some drugs can cause histamine release( d-tubocurarine and morphine).
Action of histamine: on H1 receptors include on exocrine secretion, it increases production of nasal and bronchial mucus resulting in respiratorydistress. on Bronchial smooth muscle, constriction of bronchioles results in symptoms of asthma and decreased lung capacity.
Intestinal smooth muscle, causes contraction results in intestinal cramps and diarrhea. Sensory nerve ending, causes itching and pain.
On H1 and H2 receptors On cardiovascular system, it lowers systemic blood pressure by reducing peripheral resistance. Causes positive chronotropism and a positive inotropism. On skin, dilatation and increasepermeability of the capillaries results in leakage of proteins and fluid into the tissues. In the skin, this result in the classic " triple response": reddening due to local vasodilatation, wheal formation, and flare.
On H2 receptors On stomach, causes stimulation of gastric hydrochloric acid secretion.
Histamine H3 receptors act as presynapticautoreceptors that inhibit the synthesis and release of histamine in the histaminergic neurones in the central nervous system (CNS( They also occur as hetero-receptors on nonhistaminergic neurones, modulating the release of other neurotransmitters such as 5-hydroxytryptamine, dopamine, acetylcholine, noradrenaline and GABA in the CNS and periphery.
The H4receptor is expressed in various cells of the immunesystem and mast cells and induces the chemotaxis of, for example, eosinophils and mast cells. It has also been identified on lymphocyteT cells and basophils. It has been suggested that the H4 receptor is involved, along with the H2 receptor, in the control of IL-16release from human lymphocytes, and it has been speculated that an H4-selectiveantagonist might be useful in helping to treat asthma.
Antihistamines: The effects of histamine can be opposed in three ways: 1-by using a drug with opposite effects e.g. epinephrine. 2-by blocking histamine binding to its site of action( receptors ) e.g. using competitive H1- and H2- receptor antagonists. 3-by preventing the release of histamine from storage cells; glucocorticoids, sodium cromoglicate and β2-agonists can suppress IgE - induced release from mast cells.
In this part, we will deal with H1 antihistamines which are H1 receptors blockers that do not influence the formation or release of histamine but they block the receptor-mediated response of a target tissue. They have no effect on histamine-induced gastric secretion.
The H1 receptor blockers can be divided into 1- First- generation 2- Second- generation drugs. First-generation drugs are 1- Widely used 2- Effective 3- Inexpensive. 4-Most of these drugs penetratetheCNS 5- Cause sedation. 6-Interact with other receptors 7- Producing a variety of unwanted adverseeffects.
By contrast, the second-generation agents are 1- Specific for H1 receptors 2- Do notpenetrate the blood-brainbarrier, 3- LessCNStoxicity than the first-generation drugs. Generally, they have longerduration of action permit singledaily dose.
Pharmacokinetics: H1 receptors blockers are wellabsorbed after oral administration with average plasma t1/2 is 4-6 hr. except for meclizine which has a t1/2 12-24 hr. H1 receptor blockers have highbioavailability and are distributed in alltissues, including the CNS.
All first-generation H1 antihistamines and some second-generation H1 antihistamines such as loratadine and desloratadine are metabolized by the hepatic cytochrome P450 system. Cetirizine is excreted largely unchanged in the urine and fexofenadine is excreted largely unchanged in the feces. Tolerance to the action of H1 antihistamines has not been observed.
Therapeutic uses: 1- allergic and inflammatory conditions, especially those are caused by antigens acting on IgE antibody-sensitized mast cells. However, the H1 receptors blockers are ineffectiveintreating bronchial asthma, because histamine is only one of several mediators of that condition and glucocorticoids show greater anti-inflammatory effects than H1 antihistamines in such case. Antihistamines are mosteffective when used prophylacticallybeforeallergenexposure rather than as needed.
2-motion sickness and nausea: along with the antimuscarinic agent scopolamine, certain H1 receptor blockers such as diphenhydramine, dimenhydrinate, cyclizine, meclizine and hydroxyzine are the most effective agents for prevention of the symptoms of motion sickness. The antihistamines prevent or diminish vomiting and nausea mediated by both the chemoreceptor and vestibular pathways. 3- Somnifacients( sleep producing): although they are not the medication of choice, many first-generation antihistamines, such as diphenhydramine and doxylamine, have strongsedative properties and are used in the treatment of insomnia.
Side effects: First-generation H1 receptor blockers have a lowspecific i.e. they interact not only with histamine receptors but with muscarinic cholinergic receptors, α-adrenergic receptors and serotonin receptors. The extent of interaction with these receptors and, as a result, the nature of thesideeffectsvary with the structure of the drug. Some side effects may be undesirable, and others may have therapeuticvalue and the incidence and severity of adversereactions for a given drug varies between individual subjects.
1- sedation, this the mostcommon adverse effects seen with first-generation and less with the second-generation drugs, which do not readily enter the CNS. Other CNS effects include tinnitus, fatigue, dizziness, lassitude, incoordination, blurred vision and tremors. 2- dry mouth.
3- drug interaction like potentiation of the effects of other CNS depressants. 4- overdose, although the margin of safety of H1 receptor blockers is relatively high and chronictoxicity is rare, acutepoisoning is relatively common, especially in young children. The most common and dangerouseffects of acute poisoning are those on the CNS including hallucinations, excitement, ataxia and convulsions. Ifuntreated the patient may experience a deepeningcoma and collapse of the cardiorespiratory system
5-Terfenadine can prolong the QT interval on the surface ECG. This is especially likely to occur when 1- The recommended dose is exceeded 2- The drug is administered with substances that blockhepatic metabolism (erythromycin, ketoconazole and grapefruit juice). Fexofenadine is the activemetabolite of terfenadine and appears safe in this respect
Histamine H2 receptor blockers: They block H2 receptors with no or little H1 receptors, their clinical use is as inhibitors of gastric acid secretion in the treatment of ulcers e.g. cimetidine, famotidine, nizatidine, ranitidine.
